AmorChem invests in UdeM project targeted at atherosclerosis
AmorChem has partnered with Québec commercialization hub Univalor in an investment in a drug project aimed at stopping the development of atherosclerosis. The value of the investment was not disclosed. Based on the work of Dr. Huy Ong and his colleagues at the Université de Montréal, the project focuses on factors associated with the onset and progression of atherosclerosis, an underlying cause of ischemic heart disease and related cardiovascular complications. Managed by Montréal-based venture capital firm GeneChem, AmorChem invests in R&D-stage initiatives to enable pre-clinical proof-of-concept in a semi-virtual mode.
24 July 2014•4 mins read
